University of Pennsylvania Study Advances Anti-Aging Market

Liberty Biopharma (TSXV:LTY) reported that a study from the Perelman School of Medicine at the University of Pennsylvania found adult stem cells collected from human fat are distinctly more stable than other stem cells. These, in turn, have the potential for use in new therapies for the prevention and treatment of aging-related diseases.
As quoted in the press release:

“The findings of this study are encouraging for the ASC therapies that are being developed by Liberty Biopharma,” stated Dr. Richard Cook, MD, MSc, FRCSC, Chief Medical Officer of Liberty Biopharma. “The University of Pennsylvania researchers’ findings suggest that ASCs may be particularly useful for anti-aging therapies. The study also demonstrated that ASCs are very robust in patients as old as 64 years of age. If the findings from this study are correct, the Liberty Biopharma System for isolating fresh ASCs may be able to support therapeutic options for older patients, whose need for stem-cell therapies is often greater.”

Click here for the full press release.